• Mission

    BforCure is a multidisciplinary biotech that innovates in portable biodetection

    through Microfluidics achieving very high speed and accurate quantitative PCR.

  • What is the BforCure plateform?

    A revolutionary portable biodetection plateform adressing a wide range of markets such as Defense, Healthcare, Environment & Research.


    It delivers in less than 15 minutes from sample to results with state of the art sensitivity and accuracy performance.

  • Our expertise

    BforCure team gathers experts in microfluidics, molecular biology, microbiology, advanced mechanical design, thermal management, electrical engineering, system engineering, bioinformatics, software, etc... to solve the most challenging problems of bio-detection. Based on the patented Fastgene technology, our first products use quantitative polymerase chain reaction (qPCR) to achieve ultra-fast, ultra -sensitive multiplex assays.

  • Promising company

    BforCure technology won the "Laureate of the World Innovation 2030 Challenge" for innovative ideas and technologies.

    It was awarded a €8M funding by the French General Secretary for investment to become a “future potential world leader of the medical diagnostic market based on microfluidic technologies”.

  • Investors & corporates

    If you are an investor or a corporate and you want to be part of the next revolution of diagnostic, do not hesitate to contact us at contact@bforcure.com, we are always open to new fruitful partnerships.

  • Management

    An association of experienced entrepreneurs

    Maël LE BERRE, PhD


    Georges SALEM, MD


    Christophe PANNETIER, PhD


    Cyril CERVEAU

    General Manager

  • Join us

    Looking for new talents to make it faster and faster


    System engineer for biodetection instruments (permanent position)

  • Our partners & sponsors

  • Contact

    Fill out the form to get in touch

  • Publication officielle

    Apport de l'activité Fastgene à BforCure par Elvesys par voie d'apport partiel d'actif


    En date du 28 novembre 2018, la société Elvesys a initié le processus d'apport de la branche d'activité autonome Fastgene au bénéfice de la société BforCure.

    Les documents 'Avis de projet d'apport scission' et de 'Projet de traité d'apport partiel d'actifs' sont téléchargeables ci-dessous :

    Avis de projet d'apport scission

    Projet de traité d'apport partiel d'actifs